Please ensure Javascript is enabled for purposes of website accessibility

Can KalVista Pharmaceuticals Stock Fly Higher?

By Cory Renauer - Feb 10, 2021 at 7:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can this under-the-radar biotech and its hereditary angioedema candidate produce more gains for investors?

The biotech industry's a wonky place where the outlook for a company's future can, and often does, change overnight. Successful clinical trial results for a potential drug from KalVista Pharmaceuticals (KALV 0.62%) caused its stock price to rocket 114% higher on Tuesday. Investors are right to wonder if there's still fuel in the tank to push it even higher.

Before making any predictions about KalVista Pharmaceuticals' future, we should take a quick look at what drove the stock higher.

Smiling scientist in the laboratory.

Image source: Getty Images.

Why KalVista Pharmaceuticals stock jumped

Investors excited about phase 2 trial results drove shares of this clinical-stage biotech about 160% higher on Tuesday morning. KalVista's lead candidate, KVD900, helped reduce acute swelling and other symptoms that afflict patients with hereditary angioedema (HAE), a rare condition affecting an estimated 10,000 Americans. 

In this double crossover study, 68 people with HAE received tablets containing a placebo or KVD900 to be taken after the first signs of an acute HAE attack. Patients that had the placebo the first time around took KVD900 before their second attack and vice versa.

Trial participants eventually reached for their usual medication 15% of the time after taking KVD900, compared to 30% of the time after taking a placebo. A majority of trial participants reported relief within an hour and 40 minutes after taking KVD900, compared to a median of 9 hours to feel relief after they took the placebo.

Why the stock could climb higher

Takeda (TAK 0.54%) markets a handful of treatments for HAE patients. Those treatments generate over $1 billion in combined annual sales. Takeda's most successful new HAE treatment, Takhzyro, is a kallikrein inhibitor that needs to be injected regularly to prevent flare-ups.

KalVista's KVD900 is a kallikrein inhibitor that can be taken orally as needed, which could be preferable for HAE patients who don't want a big injection every other week. Investors should note that KVD900 is intended for use only at the first sign of a flare-up and won't compete directly with Takhyzro.

Despite the stock's recent run-up, the company's market cap is still less than $700 million at recent prices. While KalVista Pharmaceuticals stock is priced reasonably for a company with a potential new acute HAE treatment ready for late-stage development, it doesn't look like the market has considered the rest of the company's pipeline.

Analysts following KalVista were quick to point out that successful results from KVD900 bode well for KVD824, a twice-daily pill to prevent HAE attacks that could compete directly with Takhzyro. KalVista's also developing oral factor XIIa inhibitors to treat HAE and could have one ready to enter clinical-stage trials in 2022.

Happy family walking through a hospital.

Image source: Getty Images.

What to look for

The Food and Drug Administration will probably require KalVista Pharmaceuticals to show KVD900 can succeed in another randomized controlled trial. If KalVista's really confident about KVD900's ability to succeed in the commercial setting, the company will quickly begin a pivotal study that compares it to available treatments in addition to a placebo.

Early stage clinical trials with KVD824 didn't set off any fireworks for KalVista, and it's been over a year since the company told us a larger phase 2 trial would begin in the second half of 2020. The company now expects to request permission from the FDA to begin its phase 2 trial with KVD824 before the end of March.

Tread lightly

Companies that know they have a winner tend to move fast, so KalVista's slow dance with KVD264 most likely means the company lacks confidence in its ability to compete in the commercial setting. Last December, the FDA approved the first oral prophylactic for HAE, Orladeyo, from BioCryst (BCRX -1.11%). During a study leading to its approval, Orladeyo reduced patients' angioedema attack rate by two-thirds.

KalVista Pharmaceuticals has only just begun animal studies for its third experimental HAE treatment. While the company is taking an interesting approach, it's going to be at least another year before we can apply any significant value to its third program. Since the KVD900 program is the only one we can safely assume has a significant value, this stock probably isn't worth the risk at the moment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

KalVista Pharmaceuticals, Inc. Stock Quote
KalVista Pharmaceuticals, Inc.
$9.68 (0.62%) $0.06
BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
$10.69 (-1.11%) $0.12
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
$13.93 (0.54%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.